Author response to 'Comment on "Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer" ( Ther Adv Med Oncol . 2021 Sep 30;13:17588359211049639)'.
Therapeutic advances in medical oncology（2023）
关键词
maintenance parp inhibitor,advanced ovarian cancer”,bevacizumab,ovarian cancer”,indirect treatment comparison,population-adjusted
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要